Connie Anggelis
Cardiovascular Disease · Louisville, KYNPI 1699775007
Payments from drug & device makers
Across 120 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$423
- Amgen$289
- Johnson & Johnson$255
- Abbott$150
- Medtronic$139
- Novartis$118
- plus $527 from 13 others
What the payments were for
- Food & beverage$1,901100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 30 | $423 |
| Amgen | 20 | $289 |
| Johnson & Johnson | 24 | $255 |
| Abbott | 3 | $150 |
| Medtronic | 2 | $139 |
| Novartis | 7 | $118 |
| Merck | 6 | $97 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $81 |
| E.r. Squibb & Sons, L.L.C. | 5 | $77 |
| Actelion Pharmaceuticals US, Inc. | 3 | $50 |
| Irhythm Technologies, Inc. | 2 | $33 |
| Pfizer | 2 | $32 |
| Boehringer Ingelheim | 2 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Chiesi USA, Inc. | 2 | $27 |
| Akcea Therapeutics, Inc. | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Lundbeck LLC | 1 | $16 |
| Braemar Manufacturing, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reveal LINQ$124
How this compares
$1,901 in reported general payments places this provider in the 40th percentile of 258 cardiovascular disease providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 55 | $57,492 |
| Repatha SyringeEvolocumab | 20 | $17,758 |
| Metoprolol Succinate | 77 | $857 |
| Potassium Chloride | 26 | $489 |
| Losartan Potassium | 37 | $414 |
| Amlodipine Besylate | 51 | $382 |
| Atorvastatin Calcium | 48 | $309 |
| Metoprolol Tartrate | 37 | $192 |
| Rosuvastatin Calcium | 14 | $145 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 13 | $137 |
| Spironolactone | 16 | $134 |
| Carvedilol | 21 | $131 |
| Lisinopril | 19 | $112 |
| Furosemide | 23 | $100 |
| Hydrochlorothiazide | 21 | $96 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $32 | $57,49255 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 258 cardiovascular disease providers in Kentucky.
Other cardiovascular disease in Louisville
- Dinesh KalraLouisville$739K
- Amir PirachaLouisville$590K
- Rohan SamsonLouisville$527K
- Shahab GhafghaziLouisville$404K
- Vipul PanchalLouisville$301K
- John HarrisLouisville$226K
- Joseph LashLouisville$178K
- Janet SmithLouisville$110K
- Chandhiran RangaswamyLouisville$77K
- Marcus StoddardLouisville$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.